The presence ofAspergillusmycotoxins has been confirmed in various feed and food. They represent a hid-den threat that cannot be completely prevented. In animal husbandry, they impair their productive health and, in hu-man nutrition, they can cause acute or chronic health com-plications. This article provides an overview of the most important secondary metabolites of the genus Aspergillusin terms of their occurrence, toxicity and physico-chemical properties.
- MeSH
- aflatoxiny * chemie škodlivé účinky toxicita MeSH
- Aspergillus * chemie metabolismus patogenita MeSH
- gliotoxin chemie škodlivé účinky toxicita MeSH
- karcinogeny chemie MeSH
- lidé MeSH
- ochratoxiny * chemie škodlivé účinky toxicita MeSH
- patulin chemie škodlivé účinky toxicita MeSH
- sterigmatocystin chemie škodlivé účinky toxicita MeSH
- Check Tag
- lidé MeSH
Systemic fungal diseases and antifungal resistance represent a serious problem in human medicine and con-tribute to increased patient mortality. The most common causes of these diseases are opportunistic yeasts of the genus Candida. C. albicansis considered to be the main pathogen, together with C. glabrata, C. tropicalis, C. par-apsilosis, and C.krusei. Azole antifungals predominate in the treatment of the systemic mycoses. For antifungal re-sistance in Candidaspp. some genes and their mutations are responsible, the genes ERG11, CDR1, CDR2and MDR1being considered the most important. The main target of azole antifungals is the process of ergosterol syn-thesis. Due to ergosterol crucial functions and its unique structural properties, the synthesis of ergosterol and its individual steps represent the target of most clinically available antifungals. The biofilm appears to be a signifi-cant virulence factor of the yeast Candidaspp. It allows hematogenous dissemination of cells, prevents the effect of antifungals on all cells during treatment and leads to a high level of antimicrobial resistance. The antifungal re-sistance in candidiasis often has a multifactorial origin, which must be considered in the treatment of systemic mycoses and in the development of new antifungals.
- MeSH
- antifungální látky chemie farmakologie terapeutické užití MeSH
- azoly farmakologie terapeutické užití MeSH
- biofilmy účinky léků MeSH
- Candida patogenita účinky léků MeSH
- ergosterol biosyntéza MeSH
- faktory virulence MeSH
- flukonazol farmakologie terapeutické užití MeSH
- fungální léková rezistence MeSH
- itrakonazol farmakologie terapeutické užití MeSH
- kandidóza * farmakoterapie mikrobiologie MeSH
- lidé MeSH
- vorikonazol farmakologie terapeutické užití MeSH
- Check Tag
- lidé MeSH
